Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / endostatin

endostatin

Basics

Aliases:
This biomarker is also known as:
  • COL18A1,
  • collagen alpha-1(XVIII) chain,
  • human type XVIII collagen,
  • KNO1,
  • KNO,
  • KS,
  • multi-functional protein MFP,
  • antiangiogenic agent,
  • collagen, type XVIII, alpha 1,
  • Knobloch syndrome, type 1,

View in BioMuta

Description…

COL18A1, also known as endostatin, is the alpha chain of type XVIII collagen. COL18A1 is one of the multiplexins, extracellular matrix proteins that contain multiple triple-helix domains (collagenous domains) interrupted by non-collagenous domains. COLA18A probably plays a major role in determining the retinal structure as well as in the closure of the neural tube. It also inhibits endothelial cell proliferation and angiogenesis, and may inhibit angiogenesis by binding to the heparan sulfate proteoglycans involved in growth factor signaling.

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Two
QA State: Curated

Overview

Endostatin, best known as an inhibitor of angiogenesis, has elevated serum levels in several cancers. Overexpression of endostatin and its parent extracellular matrix protein, collagen XVIII have been associated with poor prognosis in NSCLC (non-small cell lung cancer).

Performance Comment

Serum endostatin levels may be useful markers for NSCLC (non-small cell lung cancer). Endostatin is also a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html